Other research analysts also recently issued reports about the company. Vetr upgraded Endo International PLC from a hold rating to a buy rating and set a $11.34 price target for the company in a report on Tuesday, May 9th. Mizuho reiterated a buy rating and issued a $18.00 price target (up from $17.00) on shares of Endo International PLC in a report on Thursday, April 13th. Deutsche Bank AG cut their price target on Endo International PLC from $18.00 to $15.00 and set a buy rating for the company in a report on Friday, July 7th. BMO Capital Markets reissued a hold rating and set a $16.00 price objective on shares of Endo International PLC in a research note on Wednesday, May 17th. Finally, Canaccord Genuity set a $14.00 price objective on shares of Endo International PLC and gave the company a hold rating in a research note on Thursday, May 11th. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have issued a buy rating to the company’s stock. Endo International PLC has a consensus rating of Hold and a consensus price target of $14.75.
Shares of Endo International PLC (ENDP) traded up 1.04% during trading on Friday, hitting $8.72. The company’s stock had a trading volume of 5,294,100 shares. Endo International PLC has a one year low of $7.41 and a one year high of $24.93. The company has a 50-day moving average price of $10.47 and a 200-day moving average price of $11.43. The stock’s market cap is $1.95 billion.
Endo International PLC (NASDAQ:ENDP) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. The company had revenue of $875.73 million during the quarter, compared to the consensus estimate of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. Endo International PLC’s revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.86 EPS. Equities analysts predict that Endo International PLC will post $3.52 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by BNB Daily and is owned by of BNB Daily. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/19/endo-international-plc-nasdaqendp-given-hold-rating-at-oppenheimer-holdings-inc-updated-updated-updated.html.
In other news, CFO Blaise Coleman acquired 6,500 shares of the firm’s stock in a transaction on Tuesday, August 15th. The stock was bought at an average cost of $7.89 per share, with a total value of $51,285.00. Following the transaction, the chief financial officer now directly owns 13,729 shares in the company, valued at approximately $108,321.81. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Terrance J. Coughlin acquired 20,000 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was purchased at an average cost of $7.70 per share, with a total value of $154,000.00. Following the completion of the transaction, the chief operating officer now owns 181,369 shares in the company, valued at $1,396,541.30. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 36,000 shares of company stock valued at $279,460. 0.50% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the stock. HL Financial Services LLC raised its stake in shares of Endo International PLC by 1.0% in the second quarter. HL Financial Services LLC now owns 52,800 shares of the company’s stock worth $590,000 after buying an additional 500 shares during the period. Amalgamated Bank raised its stake in shares of Endo International PLC by 2.0% in the first quarter. Amalgamated Bank now owns 32,357 shares of the company’s stock worth $361,000 after buying an additional 619 shares during the period. Meeder Asset Management Inc. raised its stake in shares of Endo International PLC by 1.4% in the second quarter. Meeder Asset Management Inc. now owns 48,699 shares of the company’s stock worth $544,000 after buying an additional 677 shares during the period. Capstone Asset Management Co. raised its stake in shares of Endo International PLC by 3.1% in the second quarter. Capstone Asset Management Co. now owns 32,035 shares of the company’s stock worth $358,000 after buying an additional 960 shares during the period. Finally, Arizona State Retirement System raised its stake in shares of Endo International PLC by 1.5% in the second quarter. Arizona State Retirement System now owns 83,700 shares of the company’s stock worth $935,000 after buying an additional 1,200 shares during the period. 92.27% of the stock is owned by institutional investors.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.